Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index; 12 of the 51 sources its claims cite were checked for support.
Abstract
C3 deficiency protects against hippocampal neurodegeneration and cognitive decline in aged APP/PS1 mice despite abundant Aβ plaques.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 1 Not valid · 23 Not checked · 77 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Consistent with our previous results (5), C3 KO mice had significantly more synaptic puncta than WT mice.”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Results > Partial protection against age-related hippocampal synaptic degeneration in APP/PS1;C3 KO mice
What the sources say
- Partly supportedcites [5] Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, Frost JL, Le KX, Li S, Dodart JC, Caldarone BJ, Stevens B, Lemere CA, Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. J Neurosci 35, 13029– 13042 (2015). 26400934 PMC6605437 sourceExperimental — accuracy not yet measured
Our copy does report significantly higher synaptic puncta density in C3 KO vs WT mice, but only with age and region bounds the citing sentence drops: at P30 there were no genotype differences, at 4 months only presynaptic Vglut2-IR puncta differed (p = 0.0347) with no difference in Homer1 or colocalization, and the full increase (Vglut2 p = 0.002, Homer1 p < 0.0001, colocalization p = 0.0109) appears at 16 months in HC CA3-SR, with similar effects in DG-SM and V1 but explicitly no differences in CA1 (Results, 'Complement-deficient mice do not display age-related synapse loss'; Fig. 2 legend, 'C3 deficiency in neurodegeneration'). The unqualified statement 'C3 KO mice had significantly more synaptic puncta than WT mice' therefore overstates the source by omitting the aged-timepoint and region-specific qualifiers. The supporting evidence for the direction of the effect (and corroborating Golgi spine-density and Western blot synaptic-marker increases at 16 months) is present in the same sections. (LLM, conf=0.70)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Complement activation is elevated in human AD brain, especially in the presence of fibrillar amyloid plaques containing clusters of reactive microglia (8, 9, 11, 12)”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Discussion
What the sources say
- Supportedcites [8] Stoltzner SE, Grenfell TJ, Mori C, Wisniewski KE, Wisniewski TM, Selkoe DJ, Lemere CA, Temporal accrual of complement proteins in amyloid plaques in Down’s syndrome with Alzheimer’s disease. Am J Pathol 156, 489– 499 (2000). 10666378 PMC1850044 source
The paper states that classical complement activation has been observed in AD brain and that compacted amyloid plaques in AD are often associated with activated microglia and complement proteins. Its Discussion further links abundant complement proteins in compacted plaques with activated microglia in AD-type lesions. The indexed passages provide section labels but no page numbers. (LLM, conf=0.86)
- Not checked yetcites [9] Eikelenboom P, Hack CE, Kamphorst W, Rozemuller JM, Distribution pattern and functional state of complement proteins and alpha 1-antichymotrypsin in cerebral beta/A4 deposits in Alzheimer’s disease. Res Immunol 143, 617– 620 (1992). 1455052 source
- Not checked yetcites [11] Veerhuis R, Histological and direct evidence for the role of complement in the neuroinflammation of AD. Curr Alzheimer Res 8, 34– 58 (2011). 21143154 source
- Not checked yetcites [12] Tenner AJ, Complement in Alzheimer’s disease: opportunities for modulating protective and pathogenic events. Neurobiol Aging 22, 849– 861 (2001). 11754992 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We recently demonstrated that C3-deficiency spared age-dependent synaptic and neuronal loss in a region-specific manner, and protected against cognitive impairment in normal aging of C57BL/6 mice (5).”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Introduction
What the sources say
- Supportedcites [5] Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, Frost JL, Le KX, Li S, Dodart JC, Caldarone BJ, Stevens B, Lemere CA, Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. J Neurosci 35, 13029– 13042 (2015). 26400934 PMC6605437 source
The section 'Complement-deficient mice do not display age-related HC neuron loss' (p. ~ Results) states that age-dependent, region-specific synapse and neuron loss seen in WT C57BL/6J mice (CA3-SR, DG-SM reduced; CA1 spared) was rescued in aged male C3 KO mice, who had more synaptic puncta, higher SYP density and synaptic protein levels, higher LTP and more CA3 neurons. The section 'Complement C3-deficient mice do not display age-dependent behavioral deficits' states that C3 deficiency significantly protected mice against age-related cognitive decline, and the Summary ('C3 deficiency in neurodegeneration') reiterates that these age-related effects were spared in C3 KO mice. All elements of the citing sentence — C3-deficiency, sparing of age-dependent synaptic and neuronal loss in a region-specific manner, protection against cognitive impairment, and normal aging of C57BL/6 mice — are carried by our copy. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Previously, we reported an age-dependent loss of CA3 neurons in 16 month-old C57BL/6 mice (5).”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Discussion
What the sources say
- Supportedcites [5] Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, Frost JL, Le KX, Li S, Dodart JC, Caldarone BJ, Stevens B, Lemere CA, Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. J Neurosci 35, 13029– 13042 (2015). 26400934 PMC6605437 source
The Results section, “Complement-deficient mice do not display age-related HC neuron loss,” reports significantly fewer CA3 neurons in 16-month-old wild-type mice than at P30. The paper identifies the wild-type mice as C57BL/6J. The 16-month versus 4-month comparison was not significant, so the demonstrated loss is relative to P30. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“16-month-old APP/PS1;C3 KO mice performed significantly better on a learning and memory task than APP/PS1 mice, despite having more cerebral Aβ plaques.”
- Also stated in: § Sparing of cognitive decline in plaque-burdened aged APP/PS1;C3 KO mice · plain
“Reversal learning in APP/PS1;C3 KO mice was similar to that of WT mice and C3 KO mice, and was significantly better than that of APP/PS1 mice on Days 4 and 5”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Sparing of cognitive decline in plaque-burdened aged APP/PS1;C3 KO mice · plain
48 more claims
Create a free account to see all 111 claims and to verify the 39 references still open.
- Probably not a substantial claim. 35
- It may state two separate claims as one. 35
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Actually, inflammation even happens earlier than protein aggregation.”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“increasing evidence demonstrate that immune signaling may not just be a consequence of protein aggregation in the brain, but that it actually causes the buildup of aggregates at the earliest stages of the disease process.15–17”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, IFN-γ-induced C3 expression in an amyloidogenic mouse model reduced plaque load but resulted in increased loss of synapses and cognitive dysfunction [152, 284].”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [284]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings align with previous reports suggesting that plaque morphology, rather than total amyloid burden, may be a key factor in neurotoxicity and disease progression and suggest that this could be an important role for plaque‐associated PLCγ2 expressing microglia (Casali et al. 2020; Shi et al. 2017; Yuan et al. 2016).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Shi et al. 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, recent data indicate that microglia and astrocytes coordinate their functions in many ways, both in the healthy and diseased brain [14–21].”
From Crosstalk between astrocytes and microglia results in increased degradation of α-synuclein and amyloid-β aggregates (2021) · cites this paper as [17]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Discussion
“Recently, Hong et al. reported similar Aβ oligomer-induced, complement-mediated and microglia-dependent synaptic loss in young, pre-plaque AD mice that was rescued by the genetic deletion of C1q or C3, or by treatment with a C1qa blocking antibody (8).”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > References
“10. Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B, Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712– 716 (2016). 27033548 PMC5094372”
Citations
Cites
1 retracted
Bialas, A. R., & Stevens, B. (2013) · Nature Neuroscience · doi:10.1038/nn.3560 · Cited by 519
Self-citationRetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“Synapse loss is an early and important change in AD brain (41), and hippocampal synapse loss is observed in APP/PS1 mice (28, 29).”
BackgroundTerry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089
Self-citationComplement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343
Self-citationThe Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313
Self-citationMicroglia promote learning-dependent synapse formation through brain-derived neurotrophic factor
Parkhurst, C. N., Yang, G., Ninan, I., Savas, J. N., Yates, J. R., Lafaille, J. J., Hempstead, B. L., Littman, D. R., & Gan, W.-B. (2013) · Cell · doi:10.1016/j.cell.2013.11.030 · Cited by 2,599 · cited 1×
“Furthermore, mice deficient in BDNF in microglia have deficits in learning andhippocampal synapse formation, indicating thatmicroglial BDNF signaling plays an important role in hippocampal function (60).”
BackgroundSynapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Cited by
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935
Microglia emerge as central players in brain disease
Salter, M. W., & Stevens, B. (2017) · Nature Medicine · doi:10.1038/nm.4397 · Cited by 1,767
Self-citationRole of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
Metadata
- Authors
- Shi, Q., Chowdhury, S., Ma, R., Le, K. X., Hong, S., Caldarone, B. J., Stevens, B., & Lemere, C. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Boston Children's Hospital (US)
- Corresponding author
- Lemere, Cynthia A.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-05-31
- Volume
- 9
- Issue
- 392
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC6936623
- OpenAlex
- W2618794795
- Semantic Scholar
- 9b3f6a14369dd65bfc394e92ccb26bd20b83ccd0
- Cited by
- 593
- References
- 70
- Citations by year
- 2026: 47 · 2025: 72 · 2024: 75 · 2023: 71 · 2022: 66 · 2021: 88 · 2020: 64 · 2019: 50 · 2018: 43 · 2017: 17
- FWCI
- 35.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (award298479, R21 AG044713)
- BrightFocus Foundation (award298478, A2016425F)
- Fidelity Biosciences (award298481, (F-PRIME), award298470, F-PRIME)
- Edward R and Anne G Lefler (award298482, Fellowship)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Keywords
- complement C3, complement system, neurodegeneration, Alzheimer's disease, APP/PS1 mice, amyloid plaques, microglia, synaptic loss, neuronal loss, aging, glial response
- MeSH terms
- Aging, Animals, Astrocytes, Complement C3, Gliosis, Hippocampus, Mice, Inbred C57BL, Nerve Degeneration, Solubility, Synapses, Cytokines, Amyloid beta-Protein Precursor, Mice, Knockout, Presenilin-1, Plaque, Amyloid, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. https://app.cochat.ai/papers/10.1126/scitranslmed.aaf6295
- The paper
- Shi, Q., Chowdhury, S., Ma, R., Le, K. X., Hong, S., Caldarone, B. J., Stevens, B., & Lemere, C. A. (2017). Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aaf6295
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.